The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: Results from the TUXEDO-3 phase II trial.
 
Matthias Preusser
Honoraria - Abbvie; Adastra Pharmaceuticals; AstraZeneca; Bayer; BMJ Journals; Bristol-Myers Squibb; CMC Contrast; Daiichi Sankyo; Gan & Lee; Gerson Lehrman Group; GlaxoSmithKline; Lilly; Medahead; MedMedia; Merck Sharp & Dome; Mundipharma; Novartis; Roche; Sanofi; SERVIER; Telix Pharmaceuticals; Tocagen
Consulting or Advisory Role - AbbVie; Adastra Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; CMC Contrast; Daiichi Sankyo/Astra Zeneca; Gan & Lee; Gerson Lehrman Group; GlaxoSmithKline; Lilly; Merck Sharp & Dome; Mundipharma; Novartis; Roche; Sanofi; SERVIER; Tocagen
Research Funding - AbbVie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme; Novartis (Inst); Roche (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Mundipharma; Roche; SERVIER
 
Javier Garde
No Relationships to Disclose
 
Maria Gion
Honoraria - AstraZeneca Spain; Gilead Sciences; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca Spain; Gilead Sciences; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca Spain; Gilead Sciences; Pfizer; Roche
 
Manuel Ruiz
No Relationships to Disclose
 
Juan García-Mosquera
No Relationships to Disclose
 
Richard Greil
Stock and Other Ownership Interests - Lilly (Inst); Novo Nordisk (Inst)
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - Abbvie; Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Maria Valero
Speakers' Bureau - Eisai; Gilead Sciences; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi/Aventis; Seagen
Research Funding - Quironsalud
 
Miriam Arumí
No Relationships to Disclose
 
Giulia Raimondi
Other Relationship - MedSIR
 
Marta Campolier
Other Relationship - MedSIR
 
Paula Gonzalez-Alonso
Other Relationship - MedSIR
 
Jose Guerrero-Martinez
Other Relationship - MedSIR
 
Antonio Llombart-Cussac
Honoraria - AstraZeneca Spain; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Agendia; AstraZeneca Spain; Gilead Sciences; Guardant Health; Lilly; Menarini; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Gilead Sciences
Research Funding - Novartis (Inst); Roche/Genentech (Inst)
Expert Testimony - Menarini
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Pfizer; Roche
 
Felicitas Oberndorfer
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Merck Sharp & Dohme
 
Maximilian Marhold
Consulting or Advisory Role - Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer
Speakers' Bureau - Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer
Research Funding - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis
 
Marta Vaz Batista
Honoraria - Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - AstraZeneca Spain
 
Anna Berghoff
No Relationships to Disclose
 
Julia Furtner
Consulting or Advisory Role - Novartis; Seagen
Speakers' Bureau - SanovaWorks; Seagen
 
Thorsten Fuereder
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Merck KGaA; MSD; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; BeiGene; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Invios; Invios; Janssen; Lilly; Merck KGaA; MSD; PharmaMar; Takeda
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Kura Oncology (Inst); Merck KGaA (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Merck KGaA; MSD
 
Rupert Bartsch
Honoraria - AstraZeneca; Daiicho; Lilly; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi; Eisai; Lilly; MSD Oncology; MSD Oncology; Novartis; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Puma Biotechnology; Roche; Seagen
Research Funding - Daiichi (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Pfizer; Pfizer; Roche; Roche